Hydrochloric Acid → HCID 178522488, 화합물
반응식
C(OC([N:8]1[CH2:13][CH2:12][C:11]2[N:14]=[C:15]([NH:17][C:18]([C:20]3[C:28]4[NH:27][C:26]([NH:29][C:30]([C:32]5[N:33]=[CH:34][C:35]6[C:40]([CH:41]=5)=[CH:39][CH:38]=[CH:37][CH:36]=6)=[O:31])=[N:25][C:24]=4[CH:23]=[CH:22][CH:21]=3)=[O:19])[S:16][C:10]=2[CH2:9]1)=O)(C)(C)C.Cl>CO>[N:14]1[C:11]2[CH2:12][CH2:13][NH:8][CH2:9][C:10]=2[S:16][C:15]=1[NH:17][C:18]([C:20]1[C:28]2[NH:27][C:26]([NH:29][C:30]([C:32]3[N:33]=[CH:34][C:35]4[C:40]([CH:41]=3)=[CH:39][CH:38]=[CH:37][CH:36]=4)=[O:31])=[N:25][C:24]=2[CH:23]=[CH:22][CH:21]=1)=[O:19]참가 물질
4
실험 절차
To a solution of 0.2 g (0.35 mmol) of 2-({2-[(isoquinoline-3-carbonyl)-amino]-3H-benzoimidazole-4-carbonyl}-amino)-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid tert-butyl ester in methanol (1 mL) was added HCl solution (5 mL, 4M HCl in 1,4-dioxane). The mixture was stirred at room temperature for 30 min. The conversion was checked by LCMS. After removal of the organic phase, the residue was diluted with DCM (50 mL) and the organic phase was washed with sat. aq. Na2CO3 solution, water, brine, dried over Na2SO4 and concentrated to afford 160 mg (100%) of isoquinoline-3-carboxylic acid [7-(4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-2-ylcarbamoyl)-1H-benzoimidazol-2-yl]-amide. LCMS: 470 (M+1)+.